NEW YORK, November 16, 2016 /PRNewswire/ --
Companies in the Medical Laboratories and Research industry are focused
On Tuesday, shares in California headquartered Organovo Holdings Inc. recorded a trading volume of 717,654 shares. The stock ended the day at $3.30, rising 0.61%. The Company's shares have gained 32.53% on an YTD basis. The stock is trading above its 200-day moving average by 4.95%. Furthermore, shares of Organovo Holdings, which focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs, have a Relative Strength Index (RSI) of 54.93.
On November 03rd, 2016, Organovo reported Q2 FY17 total revenue of $1.4 million, which increased 358% versus Q2 FY16. The Company ended Q2 FY17 with cash and cash equivalents balance of $51.7 million. Organovo's net cash utilization during the period was $6.8 million. Visit us today and access our complete research report on ONVO at:
Madison, New Jersey headquartered Quest Diagnostics Inc.'s stock finished yesterday's session 0.12% higher at $85.20. A total volume of 1.80 million shares was traded, which was above their three months average volume of 1.17 million shares. The Company's shares have gained 2.60% in the last one month, 1.09% over the previous three months, and 22.29% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 2.72% and 10.28%, respectively. Furthermore, shares of Quest Diagnostics, which provides diagnostic testing information and services in the US and internationally, have an RSI of 60.62.
On November 11th, 2016, Quest Diagnostics announced that it has raised its outlook for revenue growth for the period 2017-2020 to be 3%-5%. Earnings for the same period are expected to grow faster than revenues in the mid-to-high single digit range. Additionally, the company has raised its common stock dividend by 12.5% to an annual rate of $1.80 per share.
On November 14th, 2016, research firm UBS upgraded the Company's stock rating from 'Neutral' to 'Buy'. The research firm also revised upwards its previous target price from $88 to $90. The complimentary report on DGX can be downloaded at:
At the closing bell on Tuesday, shares in Waltham, Massachusetts headquartered Alere Inc. climbed 2.61%, ending the day at $36.16 with a total trading volume of 524,699 shares. The stock is trading 14.45% below its 50-day moving average. Shares of the Company, which provides professional diagnostic products and services for infectious and cardiometabolic disease, and toxicology in the US, Europe, and internationally, have an RSI of 27.04.
On November 07th, 2016, research firm Canaccord Genuity reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $53 a share to $50 a share.
On November 14th, 2016, Alere announced that it has posted a fact sheet on its website providing additional information regarding its subsidiary Arriva Medical, LLC's relationship with the Centers for Medicare & Medicaid Services and its enrollment in the National Mail Order Competition Bid Program for Diabetes Testing Supplies. The company stated that the fact sheet highlights, among other things, the data that supports Alere's belief that the Medicare claims in question were submitted in response to valid refill orders from Medicare beneficiaries or their caregivers. Register for free on Stock-Callers.com and access the latest research report on ALR at:
California headquartered DexCom Inc.'s stock ended the day 3.98% higher at $71.53. A total volume of 1.91 million shares was traded, which was higher than their three months average volume of 1.00 million shares. The Company's shares are trading 4.48% below their 200-day moving average. Additionally, shares of DexCom, which focuses on the design, development, and commercialization of continuous glucose monitoring systems in the US and internationally, have an RSI of 46.17.
On November 02nd, 2016, research firm Canaccord Genuity reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $100 a share to $70 a share.
On November 14th, 2016, Dexcom announced that Health Canada has approved its Dexcom G5 Mobile CGM system for "non-adjunctive" use by people with diabetes aged 2 years and older. Canada is the first country in North America to approve the device with the non-adjunctive indication. Get free access to your research report on DXCM at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
A prosthetic heart valve is an artificial device surgically implanted into the heart to replace a ...
PUVA or photochemotherapy is used to treat several skin disorders with the help of UV light and the ...
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...View All